Vumon

(teniposide)

ApprovedSmall molecule

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Vumon is one of 195 small molecule programs targeting Adult Acute Lymphoblastic Leukemia. It is currently in Approved.

Indications

Total Trials

Active Trials

194

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Adult Acute Lymphoblastic LeukemiaActive, not recruiting

LymphomaActive, not recruiting

Germ Cell TumorActive, not recruiting

LeukemiaActive, not recruiting

Precursor B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Adult Acute Lymphoblastic LeukemiaApproved

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Germ Cell TumorPhase 2

Active, not recruiting

LeukemiaPhase 2

Active, not recruiting

Precursor B-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaApproved

Active, not recruiting

Mantle Cell LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Vumon

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

2 9

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

1 10

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Germ Cell Tumor

NCT07188441

Q3 2029

Phase 2/3Not yet recruiting

Newly Diagnosed

NCT07185373

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Completed·GGoethe University·Phase 4·NCT00198991·1,883 enrolled

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Unknown status·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00343369·550 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00853008·100 enrolled

Newly Diagnosed1 trial

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

Not yet recruiting·HHuashan Hospital·Phase 2/3·NCT07185373·215 enrolled

Leukemia1 trial

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 2·NCT00002531

4 more indications

Lymphoma1 trial

Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·NNorthwestern University·Phase 1/2·NCT00004916

Central Nervous System1 trial

Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

Unknown status·—·N/A·NCT06048107·20 enrolled

Mantle Cell Lymphoma1 trial

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Completed·NNorthwestern University·Phase 2·NCT00004231

Germ Cell Tumor1 trial

Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.

Recruiting·CChengcheng Guo·Phase 2·NCT07188441·40 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 14, 1992

VUMON

NDA NDA020119

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for teniposide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — teniposide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for teniposide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020119). U.S. Food & Drug Administration.
[5]
SEC EDGAR — McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Vumon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2029

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Adult Acute Lymphoblastic Leukemia1 trial

Newly Diagnosed1 trial

Leukemia1 trial

Lymphoma1 trial

Central Nervous System1 trial

Mantle Cell Lymphoma1 trial

Germ Cell Tumor1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News